Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAF^V600 mutated melanoma.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-09-02 DOI:10.2217/mmt-2015-0005

Sarah Sammons, Donita Brady, Linda Vahdat, April Ks Salama

引用次数: 16

Abstract

The successful targeting of oncogenic BRAF^V600 represents one of the landmark breakthroughs in therapy for advanced melanoma. While the initial clinical benefit can be dramatic, resistance is common due to a number of mechanisms, including MAPK pathway reactivation. Recent data have revealed a novel role for copper (Cu) in BRAF signaling with potential clinical implications. The history, preclinical data and efficacy of Cu chelating agents in cancer, specifically tetrathiomolybdate, will be reviewed with a focus on the rationale for targeting the MAPK cascade in melanoma through novel combination strategies.

Abstract Image

查看原文本刊更多论文

铜抑制作为癌症治疗:铜螯合剂治疗BRAFV600突变黑色素瘤的基本原理

BRAFV600的成功靶向是晚期黑色素瘤治疗中具有里程碑意义的突破之一。虽然最初的临床益处可能是巨大的，但由于多种机制，包括MAPK通路的再激活，耐药是常见的。最近的数据揭示了铜(Cu)在BRAF信号传导中的新作用，具有潜在的临床意义。本文将回顾铜螯合剂(特别是四硫钼酸盐)治疗癌症的历史、临床前数据和疗效，并重点讨论通过新的联合策略靶向黑色素瘤中MAPK级联的基本原理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.

Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma.

Abstract

Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAF^V600 mutated melanoma.